IL2 and melanoma: The initial studies in patients with melanoma evaluated ipilimumab at single or multiple doses ranging from 0.1 to 20 mg/kg, either as monotherapy or in combination with IL-2,47 gp100 melanoma peptide vaccine,48 or chemotherapy.49 These studies documented objective responses with ipilimumab in patients with melanoma, which were durable in many cases.